MRC Laboratory of Molecular Biology

One of the world's leading research institutes, our scientists are working to advance understanding of biological processes at the molecular level - providing the knowledge needed to solve key problems in human health.

Home > LMB In The News > Heptares Therapeutics extends multi-fte chemistry collaboration with oxygen healthcare (o2h)

Heptares Therapeutics extends multi-fte chemistry collaboration with oxygen healthcare (o2h)

Published on

“Executives from Heptares Therapeutics (Welwyn Garden City, UK) and O2h (Cambridge, UK) announced today an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares… Heptares is a drug discovery company focused on identifying novel drug candidates targeting validated G-protein-coupled receptors (GPCRs) in several disease areas. Heptares was founded in 2007 and its StaR technology arose out of the pioneering work of Heptares’ founding scientists at the MRC Laboratory of Molecular Biology (Cambridge, UK) and the National Institute for Medical Research (London, UK).” More…